Atea Pharmaceuticals, Inc. Operating Lease Cost
Atea Pharmaceuticals, Inc. (AVIR) reported Operating Lease Cost of $162.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-12
- Atea Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2026-06-30 was $162.00K, a 0.00% change year-over-year.
- Atea Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2026-03-31 was $161.00K, a 0.00% change year-over-year.
- Atea Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2025-12-31 was $161.00K, a 0.00% change year-over-year.
- Atea Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2025-09-30 was $162.00K, a 0.00% change year-over-year.
- Atea Pharmaceuticals, Inc. operating lease, cost for fiscal 2025 was $646.00K, a 0.00% change from fiscal 2024.
- Atea Pharmaceuticals, Inc. operating lease, cost for fiscal 2024 was $646.00K, a 0.00% change from fiscal 2023.
- Atea Pharmaceuticals, Inc. operating lease, cost for fiscal 2023 was $646.00K, a 20.35% decline from fiscal 2022.
- Atea Pharmaceuticals, Inc. operating lease, cost for fiscal 2022 was $811.00K, a 188.61% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $162.00K 10-Q · filed 2026-08-12 | $323.00K 10-Q · filed 2026-08-12 | $484.00K derived: sum of 3 quarters · filed 2026-08-12 | $646.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $161.00K 10-Q · filed 2026-05-12 | $322.00K derived: sum of 2 quarters · filed 2026-05-12 | $484.00K derived: sum of 3 quarters · filed 2026-05-12 | $646.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $161.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $323.00K derived: sum of 2 quarters · filed 2026-03-05 | $485.00K derived: sum of 3 quarters · filed 2026-08-12 | $646.00K 10-K · filed 2026-03-05 | |
| 2025-09-30 | $162.00K 10-Q · filed 2025-11-12 | $324.00K derived: sum of 2 quarters · filed 2026-08-12 | $485.00K 10-Q · filed 2025-11-12 | $646.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $162.00K 10-Q · filed 2026-08-12 | $323.00K 10-Q · filed 2026-08-12 | $484.00K derived: sum of 3 quarters · filed 2026-08-12 | $646.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $161.00K 10-Q · filed 2026-05-12 | $322.00K derived: sum of 2 quarters · filed 2026-05-12 | $484.00K derived: sum of 3 quarters · filed 2026-05-12 | $646.00K derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $161.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $323.00K derived: sum of 2 quarters · filed 2026-03-05 | $485.00K derived: sum of 3 quarters · filed 2026-03-05 | $646.00K 10-K · filed 2026-03-05 | |
| 2024-09-30 | $162.00K 10-Q · filed 2025-11-12 | $324.00K derived: sum of 2 quarters · filed 2025-11-12 | $485.00K 10-Q · filed 2025-11-12 | $646.00K derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $162.00K 10-Q · filed 2025-08-07 | $323.00K 10-Q · filed 2025-08-07 | $484.00K derived: sum of 3 quarters · filed 2025-08-07 | $646.00K derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $161.00K 10-Q · filed 2025-05-12 | $322.00K derived: sum of 2 quarters · filed 2025-05-12 | $484.00K derived: sum of 3 quarters · filed 2025-05-12 | $646.00K derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | $161.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $323.00K derived: sum of 2 quarters · filed 2025-03-06 | $485.00K derived: sum of 3 quarters · filed 2025-03-06 | $646.00K 10-K · filed 2025-03-06 | |
| 2023-09-30 | $162.00K 10-Q · filed 2024-11-07 | $324.00K derived: sum of 2 quarters · filed 2024-11-07 | $485.00K 10-Q · filed 2024-11-07 | $647.00K derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $162.00K 10-Q · filed 2024-08-07 | $323.00K 10-Q · filed 2024-08-07 | $485.00K derived: sum of 3 quarters · filed 2024-08-07 | $670.00K derived: sum of 4 quarters · filed 2024-08-07 | |
| 2023-03-31 | $161.00K 10-Q · filed 2024-05-14 | $162.00K 10-Q · filed 2023-05-08 | $323.00K derived: sum of 2 quarters · filed 2024-05-14 | $508.00K derived: sum of 3 quarters · filed 2024-05-14 | $740.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $162.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $347.00K derived: sum of 2 quarters · filed 2024-02-28 | $579.00K derived: sum of 3 quarters · filed 2024-02-28 | $811.00K 10-K · filed 2024-02-28 | |
| 2022-09-30 | $185.00K 10-Q · filed 2023-11-08 | $417.00K derived: sum of 2 quarters · filed 2023-11-08 | $649.00K 10-Q · filed 2023-11-08 | $719.00K derived: sum of 4 quarters · filed 2023-11-08 | |
| 2022-06-30 | $232.00K 10-Q · filed 2023-08-08 | $464.00K 10-Q · filed 2023-08-08 | $534.00K derived: sum of 3 quarters · filed 2023-08-08 | $605.00K derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | $232.00K 10-Q · filed 2023-05-08 | $302.00K derived: sum of 2 quarters · filed 2023-05-08 | $373.00K derived: sum of 3 quarters · filed 2023-05-08 | $444.00K derived: sum of 4 quarters · filed 2023-05-08 | |
| 2021-12-31 | $70.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $141.00K derived: sum of 2 quarters · filed 2023-02-28 | $212.00K derived: sum of 3 quarters · filed 2023-02-28 | $281.00K 10-K · filed 2023-02-28 | |
| 2021-09-30 | $71.00K 10-Q · filed 2022-11-07 | $142.00K derived: sum of 2 quarters · filed 2022-11-07 | $211.00K 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | $71.00K 10-Q · filed 2022-08-08 | $141.00K 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | $76.00K 10-Q · filed 2022-05-10 | $70.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |